

AMENDMENTS

In the Claims:

This listing of claims replaces all prior versions, and listings, of claims in the application.

1 (currently amended). A method of immunomodulatory treatment of insulin-dependent diabetes mellitus (IDDM) ~~therapy~~ in a mammal said method comprising administering to said mammal an immunomodulating effective amount of mycolyl arabinogalactin peptidoglycan (MAPG), ~~or a component of mycolyl arabinogalactan peptidoglycan (MAPG)~~, isolated from the cell wall of *Mycobacterium*, ~~wherein the immunomodulatory therapy is for the treatment of insulin-dependent diabetes mellitus (IDDM).~~

2-7 (cancelled).

8 (currently amended). The method according to claim 1, wherein said MAPG is administered with one or more of mycolic acids, peptidoglycan or arabinogalactan.

9 (currently amended). The method according to claim 1, wherein said MAPG ~~or a component thereof~~ is from *Mycobacterium bovis*.

~~10 (previously-presented).~~ The method according to claim 1, wherein the mammal is a human.

11 (withdrawn). A method for preventing, delaying onset of, curing, curing in association with islet and/or pancreas transplant replacement or otherwise ameliorating the effects of IDDM in a mammal said method comprising administering to said mammal an IDDM treating effective amount of one or more components of the cell wall of *Mycobacterium* or related organism or analogous components from another biological source or chemical equivalents of said components.

12 (withdrawn). A method according to claim 11 wherein the mammal is a human.

13 (withdrawn). A method according to claim 12 wherein the cell wall component is MAPG or a derivative or component thereof or their derivatives or chemical equivalents.

14 (withdrawn). A method according to claim 13 wherein the MAPG or its derivatives or components is from *M. bovis*.

15 (withdrawn). A composition of matter comprising MAPG or a derivative or a component thereof or its derivative or chemical equivalents thereof.

16 (withdrawn). A composition according to claim 15 further comprising one or more pharmaceutically acceptable carriers and /or diluents.

17 (withdrawn). A method for isolating components of MAPG for use in a therapeutic composition for preventing, delaying the onset of or otherwise ameliorating the effects of diabetes in a mammal or for use in immunomodulatory therapy said method comprising preparing cell envelopes from a species of *Mycobacterium* or related organism or other suitable biological source, subjecting said cell envelopes to glycolipid removing means to remove soluble glycolipids, treating the product so obtained to break the mycolic acids linkage and isolating said mycolic acids, treating the remaining complex to cleave linkage at rhamnose residue connecting arabinogalactan to the peptidoglycan backbone and separating and isolating arabinogalactan and peptidoglycan.

18 (withdrawn). A method according to claim 17 wherein the glycolipids are removed by repeated centrifugation in the presence of sodium dodecyl sulphate (SDS).

19 (withdrawn). A method according to claim 17 wherein the mycolic acids linkage is cleaved by saponification, base-catalysed methanolysis or ammonolysis.

20-21 (cancelled)

22 (withdrawn). Use according to claim 20 wherein the immunomodulatory therapy is for the treatment of carcinoma.

Add the following new claims:

23 (new). A method of immunomodulatory therapy in a mammal said method comprising administering to said mammal an immunomodulating effective amount of one or more components of mycolyl-arabinogalactan-peptidoglycan (MAPG) selected from the group consisting

of mycolic acids, peptidoglycan or arabinogalactan, isolated from the cell wall of *Mycobacterium*, wherein the immunomodulatory therapy is for the treatment of insulin-dependent diabetes mellitus (IDDM).

24 (new). The method according to claim 1, wherein MAPG or a component thereof is from *Mycobacterium bovis*.

25 (new). The method according to claim 23, wherein the mammal is a human.